No Data
Beigene (06160.HK) received 1,686,700 restricted stock units.
Beigene (06160.HK) issued 1.6867 million common shares on June 17, 2024, due to the ownership of restricted share units granted under the equity incentive plan (excluding company directors).
Beigene (06160) issued approximately 1.6867 million shares due to restricted share units being awarded to the beneficiary.
Beigene (06160) announced on June 17, 2024 that approximately 1.6867 million shares were issued due to the allocation of restricted share units under the equity incentive plan, excluding company directors.
Beigene (06160) issued approximately 7.1742 million shares due to the allocation of restricted share units under the equity plan.
Beigene (06160) announced that a total of approximately 7.1742 million shares were issued on June 15th and 16th, 2024 due to the attribution of restricted share units granted under the equity incentive plan.
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
BeiGene (BGNE) said Friday that preliminary data from a phase 3 study of Brukinsa in combination with venetoclax to treat patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma s
BeiGene to Present New Data From SEQUOIA Study Evaluating BRUKINSA Plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
DUBAI, United Arab Emirates--(BUSINESS WIRE)--$BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclud